Drug Profile
Research programme: therapeutic agents - Schrodinger/Takeda
Latest Information Update: 28 Jan 2024
Price :
$50
*
At a glance
- Originator Schrodinger; Takeda
- Class Antineoplastics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Neurodegenerative disorders
- No development reported Cancer
Most Recent Events
- 28 Jan 2024 No recent reports of development identified for research development in Cancer in Japan
- 28 Jan 2024 No recent reports of development identified for research development in Cancer in USA
- 18 Jan 2022 Early research development is ongoing In Cancer and Neurodegenerative disorders in Japan and USA (Schrodinger pipeline, January 2022)